1. Wada, Yuji, Naito, Tadasuke, Fukushima, Takuya, Saito, Mineki. 2024. Evaluation of ALKBH2 and ALKBH3 gene regulation in patients with adult T-cell leukemia/lymphoma. In Virology journal, 21, 316. doi:10.1186/s12985-024-02590-w. https://pubmed.ncbi.nlm.nih.gov/39633427/
2. Ke, Bingxin, Ye, Kejun, Cheng, Shaobing. 2020. ALKBH2 inhibition alleviates malignancy in colorectal cancer by regulating BMI1-mediated activation of NF-κB pathway. In World journal of surgical oncology, 18, 328. doi:10.1186/s12957-020-02106-0. https://pubmed.ncbi.nlm.nih.gov/33302959/
3. Wu, Shuang-shuang, Xu, Wei, Liu, Shan, Liu, Shi-feng, Wu, Jian-qing. 2011. Down-regulation of ALKBH2 increases cisplatin sensitivity in H1299 lung cancer cells. In Acta pharmacologica Sinica, 32, 393-8. doi:10.1038/aps.2010.216. https://pubmed.ncbi.nlm.nih.gov/21278781/